$SMTI
Sanara Medtech Inc Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022851 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$13.04M	$9.671M	$7.811M
YoY Change	123.98%	54.06%	-30.79%
Cost Of Revenue	$2.229M	$958.1K	$805.1K
YoY Change	330.55%	78.61%	71.29%
Gross Profit	$10.82M	$8.713M	$7.006M
YoY Change	103.83%	51.77%	54.32%
Gross Profit Margin	82.92%	90.09%	89.69%
Selling, General & Admin	$12.06M	$10.43M	$9.376M
YoY Change	74.31%	58.91%	73.3%
% of Gross Profit	111.52%	119.69%	133.82%
Research & Development	$1.061M	$1.067M	$204.6K
YoY Change	2875.24%	926.15%	70.53%
% of Gross Profit	9.81%	12.25%	2.92%
Depreciation & Amortization	$106.3K	$412.0K	$202.8K
YoY Change	-48.01%	306.34%	125.28%
% of Gross Profit	0.98%	4.73%	2.89%
Operating Expenses	$13.94M	$11.91M	$9.783M
YoY Change	94.66%	75.96%	74.08%
Operating Profit	-$3.122M	-$3.194M	-$2.777M
YoY Change	68.42%	211.29%	157.12%
Interest Expense	$109.7K	$63.43K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$109.7K	-$63.43K	-$379.6K
YoY Change	-43.41%
Pretax Income	-$3.232M	-$3.258M	-$3.157M
YoY Change	57.83%	170.15%	167.5%
Income Tax	-$1.700M	-$4.100M
% Of Pretax Income
Net Earnings	-$1.529M	-$3.258M	-$3.157M
YoY Change	-25.32%	170.15%	166.74%
Net Earnings / Revenue	-11.72%	-33.69%	-40.41%
Basic Earnings Per Share	-$0.18	-$0.42	-$0.41
Diluted Earnings Per Share	-$181.4K	-$416.5K	-$411.4K
COMMON SHARES
Basic Shares Outstanding	8.304M shares	7.791M shares	7.606M shares
Diluted Shares Outstanding	8.107M shares	8.163M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.29M	$12.68M	$16.14M
YoY Change	-65.15%	-48.01%	-40.93%
Cash & Equivalents	$10.29M	$12.68M	$16.14M
Short-Term Investments
Other Short-Term Assets	$1.015M	$739.5K	$624.9K
YoY Change	-0.63%	48.75%	20.18%
Inventory	$3.734M	$2.312M	$2.171M
Prepaid Expenses
Receivables	$5.421M	$3.837M	$3.555M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.57M	$19.83M	$22.49M
YoY Change	-24.45%	-31.44%	-28.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.471M	$1.514M	$1.934M
YoY Change	-7.0%	-9.31%	-7.9%
Goodwill	$3.278M
YoY Change
Intangibles	$32.22M	$21.76M
YoY Change	566.21%	474.76%
Long-Term Investments	$3.084M	$3.084M	$4.888M
YoY Change	-19.08%	-23.0%	205.48%
Other Assets
YoY Change
Total Long-Term Assets	$40.90M	$26.65M	$11.44M
YoY Change	282.34%	170.14%	52.94%
TOTAL ASSETS
Total Short-Term Assets	$20.57M	$19.83M	$22.49M
Total Long-Term Assets	$40.90M	$26.65M	$11.44M
Total Assets	$61.48M	$46.48M	$33.93M
YoY Change	62.09%	19.84%	-13.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$893.9K	$732.9K	$981.2K
YoY Change	178.13%	133.74%	165.19%
Accrued Expenses	$8.283M	$5.452M	$4.250M
YoY Change	123.58%	61.54%	53.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.206M	$6.930M	$5.231M
YoY Change	121.39%	85.0%	67.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.055M	$3.946M	$187.0K
YoY Change	7713.75%	4269.75%	-54.38%
Total Long-Term Liabilities	$7.623M	$4.097M	$187.0K
YoY Change	2096.76%	975.19%	-54.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.206M	$6.930M	$5.231M
Total Long-Term Liabilities	$7.623M	$4.097M	$187.0K
Total Liabilities	$16.83M	$11.03M	$4.902M
YoY Change	273.54%	167.19%	61.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.12M	-$21.66M
YoY Change	67.6%	130.79%
Common Stock	$64.57M	$57.86M
YoY Change	845995.83%	759999.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.46M	$36.20M	$29.03M
YoY Change
Total Liabilities & Shareholders Equity	$61.48M	$46.48M	$33.93M
YoY Change	62.09%	19.84%	-13.04%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.529M	-$3.258M	-$3.157M
YoY Change	-25.32%	170.15%	166.74%
Depreciation, Depletion And Amortization	$106.3K	$412.0K	$202.8K
YoY Change	-48.01%	306.34%	125.28%
Cash From Operating Activities	-$1.643M	-$1.154M	-$2.112M
YoY Change	14.56%	243.65%	67.66%
INVESTING ACTIVITIES
Capital Expenditures	$1.441M	-$2.090M	-$44.70K
YoY Change	-347.04%	8111.83%
Acquisitions
YoY Change
Other Investing Activities	-$2.191M	$0.00	-$249.7K
YoY Change		-100.0%	-58.39%
Cash From Investing Activities	-$750.4K	-$2.090M	-$294.4K
YoY Change	28.65%	-19.92%	-50.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-220.0K	-102.9K
YoY Change		29629.73%	-100.36%
NET CHANGE
Cash From Operating Activities	-1.643M	-1.154M	-2.112M
Cash From Investing Activities	-750.4K	-2.090M	-294.4K
Cash From Financing Activities	0.000	-220.0K	-102.9K
Net Change In Cash	-2.393M	-3.464M	-2.510M
YoY Change	18.63%	17.58%	-109.34%
FREE CASH FLOW
Cash From Operating Activities	-$1.643M	-$1.154M	-$2.112M
Capital Expenditures	$1.441M	-$2.090M	-$44.70K
Free Cash Flow	-$3.084M	$935.6K	-$2.068M
YoY Change	262.41%	-401.37%	64.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000714256
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2021Q2	us-gaap	Interest Expense InterestExpense		usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	SMTI	License Agreement As Capital Contribution From Noncontrolling Interest LicenseAgreementAsCapitalContributionFromNoncontrollingInterest		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q2	SMTI	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2021Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39678
	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
	dei	City Area Code CityAreaCode	(817)
	dei	Local Phone Number LocalPhoneNumber	529-2300
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	SMTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8303729	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12678846	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18652841	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3836844	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2861014	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	210584	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	79787	usd
CY2022Q2	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2021Q4	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2312238	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2048191	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	739457	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	917318	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	19827313	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	24608495	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1513584	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1629845	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	296626	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	412770	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21755906	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4727970	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	5017351	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	26650394	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	11787936	usd
CY2022Q2	us-gaap	Assets Assets	46477707	usd
CY2021Q4	us-gaap	Assets Assets	36396431	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	732926	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	438154	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	745492	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	155817	usd
CY2022Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1467573	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	706196	usd
CY2022Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	3827521	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	4518817	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	156959	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	203292	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6930471	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6022276	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3945579	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	151378	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	222151	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4096957	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	222151	usd
CY2022Q2	us-gaap	Liabilities Liabilities	11027428	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6244427	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8015401	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8015401	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7676662	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7676662	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	8015	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7677	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	57850750	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45867768	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21660396	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15235044	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	36198369	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	30640401	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-748090	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-488397	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35450279	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46477707	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36396431	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9670778	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6277133	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17482001	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11286569	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	958086	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	536405	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1763167	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1010838	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	8712692	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	5740728	usd
	us-gaap	Gross Profit GrossProfit	15718834	usd
	us-gaap	Gross Profit GrossProfit	10275731	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10428133	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6562144	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19803763	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11971874	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1067000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103981	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1271637	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222193	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	412028	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100807	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	614775	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	191398	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	11907161	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	6766932	usd
	us-gaap	Operating Expenses OperatingExpenses	21690175	usd
	us-gaap	Operating Expenses OperatingExpenses	12385465	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3194469	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1026204	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5971341	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2109734	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	63427	usd
	us-gaap	Interest Expense InterestExpense	63427	usd
	us-gaap	Interest Expense InterestExpense	711	usd
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-179769	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-278904	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63427	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-179769	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-443060	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-279615	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3257896	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1205973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6414401	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2389349	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12512	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34481	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-39693	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-36113	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3245384	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1171492	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6374708	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2353236	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7791431	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7496604	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7699422	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7158503	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5840236	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1750000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28939257	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	325518	usd
CY2021Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	200000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1183376	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35471635	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	297922	usd
CY2021Q2	SMTI	Capital Contribution Of Noncontrolling Interest CapitalContributionOfNoncontrollingInterest	93879	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1205973	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34657463	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1623118	usd
CY2022Q1	SMTI	Net Settlement And Retirement Of Equity Based Awards NetSettlementAndRetirementOfEquityBasedAwards	-102931	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3156505	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28515686	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	703400	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5096444	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4612645	usd
CY2022Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	220000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3257896	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35450279	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6414401	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2389349	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	614775	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	191398	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2500	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	195000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51536	usd
	us-gaap	Inventory Write Down InventoryWriteDown	159717	usd
	us-gaap	Inventory Write Down InventoryWriteDown	29834	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1288335	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	623440	usd
	us-gaap	Accretion Expense AccretionExpense	63427	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	116143	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	61629	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-278904	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1170829	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	279229	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	130797	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	423764	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	419979	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-177861	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-114707	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	294772	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	42318	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	589675	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-166081	usd
	SMTI	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	761377	usd
	SMTI	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	25327	usd
	SMTI	Increasedecreaseinaccrued Bonus And Commissions IncreasedecreaseinaccruedBonusAndCommissions	346887	usd
	SMTI	Increasedecreaseinaccrued Bonus And Commissions IncreasedecreaseinaccruedBonusAndCommissions	301981	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-117106	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-62331	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3266795	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1595895	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	80892	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25446	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	345	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2053722	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	3184278	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2384269	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3209724	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	800000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	28939257	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-102931	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	220000	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	200000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-322931	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28739257	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5973995	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23933638	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18652841	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	455366	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12678846	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24389004	usd
	us-gaap	Interest Paid Net InterestPaidNet	711	usd
	us-gaap	Stock Issued1 StockIssued1	9709089	usd
	us-gaap	Stock Issued1 StockIssued1	1750000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	3882151	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1803440	usd
	SMTI	License Agreement As Capital Contribution From Noncontrolling Interest LicenseAgreementAsCapitalContributionFromNoncontrollingInterest	93879	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zIqE2htAG7pg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82C_zNKUEdE0h7K6">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (“we”, “our”, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical and chronic wound and skin care markets. The Company’s portfolio of products, services and technologies is designed to allow the Company to deliver comprehensive wound and skin care solutions for patients in all care settings, including acute (hospitals and long-term acute care hospitals) and post-acute (wound care clinics, physician offices, skilled nursing facilities, home health, hospice, and retail). Each of the Company’s products, services, and technologies contributes to the Company’s overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective wound and skin care solutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zYgkguHLSVc5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and determined there was not a material impact on the Company’s estimates and assumptions used in preparing its unaudited consolidated financial statements as of and for the six months ended June 30, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17482001	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11286569	usd
CY2022Q2	us-gaap	Payments For Royalties PaymentsForRoyalties	50250	usd
	SMTI	Royalty Percentage RoyaltyPercentage	0.020	pure
	us-gaap	Payments For Royalties PaymentsForRoyalties	201000	usd
CY2022Q2	us-gaap	Payments For Royalties PaymentsForRoyalties	50250	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	201000	usd
CY2022Q2	us-gaap	Payments For Royalties PaymentsForRoyalties	50250	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	195000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51536	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	241909	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	64899	usd
CY2022Q2	SMTI	Other Allowances OtherAllowances	7213	usd
CY2021Q4	SMTI	Other Allowances OtherAllowances	34379	usd
	us-gaap	Inventory Write Down InventoryWriteDown	159717	usd
	us-gaap	Inventory Write Down InventoryWriteDown	29834	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	368726	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	333850	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2040941	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1972419	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	527357	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	342574	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1513584	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1629845	usd
	us-gaap	Depreciation Depreciation	194308	usd
	us-gaap	Depreciation Depreciation	35040	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	126815	usd
CY2022Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	23379885	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1623979	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21755906	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5931482	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1203512	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4727970	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y9M18D
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	420467	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	156358	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	626472	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1250279	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1250279	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1250279	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1233023	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1233023	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1912551	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8755906	usd
	us-gaap	Royalty Expense RoyaltyExpense	812966	usd
	us-gaap	Royalty Expense RoyaltyExpense	404220	usd
CY2020Q2	us-gaap	Cash Cash	500000	usd
	SMTI	Royalties Payable Minimum RoyaltiesPayableMinimum	201000	usd
CY2022Q2	us-gaap	Payments For Royalties PaymentsForRoyalties	50250	usd
	SMTI	Annual Royalty Obligation AnnualRoyaltyObligation	16080	usd
CY2022Q2	SMTI	Annual Royalty Obligation AnnualRoyaltyObligation	4020	usd
CY2022Q2	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	125966	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	SMTI	Transaction Expenses TransactionExpenses	600000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	us-gaap	Share Price SharePrice	30.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	296626	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	308337	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	75476	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	127777	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	76178	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	94016	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	154271	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	77870	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	326157	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17820	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	308337	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	156959	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	151378	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0613	pure
CY2021Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	584244	usd
CY2022Q2	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	125966	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	SMTI	Transaction Expenses TransactionExpenses	600000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	us-gaap	Share Price SharePrice	30.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q2	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	10000000.0	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	27.13
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	176344	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	4368128	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1288335	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	623440	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1038183	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3745738	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	161450	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18.13
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	178857	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	138658	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	19.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	2513	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	25.28
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	199136	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.86
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.71
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Granted Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualGrantedTerm	P8Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	155691	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.36
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	155691	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.36
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	16725	shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice	10.80
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2022Q2	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q2	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2022Q2	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2021Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	800000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2022Q2	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2021Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	2834278	usd
CY2022Q2	us-gaap	Investments Investments	3084278	usd
CY2021Q4	us-gaap	Investments Investments	5017351	usd
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-179769	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-278904	usd
CY2021Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	584244	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	79787	usd
CY2021Q1	SMTI	Net Sale NetSale	1000000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	496100	usd
CY2021Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	584244	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3900	usd
CY2021Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	78586	usd
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	1162830	usd
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	1162830	usd
CY2021Q3	SMTI	Business Acquisition Purchase Price Consideration Percentage BusinessAcquisitionPurchasePriceConsiderationPercentage	1.000	pure
CY2022Q2	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	125966	usd
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	745492	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	155817	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	210584	usd

Files In Submission

Name	View Source	Status
0001493152-22-022851-index-headers.html	Edgar Link	pending
0001493152-22-022851-index.html	Edgar Link	pending
0001493152-22-022851.txt	Edgar Link	pending
0001493152-22-022851-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20220630.xsd	Edgar Link	pending
smti-20220630_cal.xml	Edgar Link	unprocessable
smti-20220630_def.xml	Edgar Link	unprocessable
smti-20220630_pre.xml	Edgar Link	unprocessable
smti-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara Medtech Inc Stock $smti

2022 Q3 Form 10-Q Financial Statement

#000149315222022851 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara Medtech Inc Stock $smti

2022 Q3 Form 10-Q Financial Statement

#000149315222022851 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara Medtech Inc Stock $smti